The DOI matches its Crossref record; 104 of the 107 references it cites were found in a registry or an index.
Glycaemic variability in diabetes: clinical and therapeutic implications
Abstract
Glycaemic variability is an integral component of glucose homoeostasis. Although it has not yet been definitively confirmed as an independent risk factor for diabetes complications, glycaemic variability can represent the presence of excess glycaemic excursions and, consequently, the risk of hyperglycaemia or hypoglycaemia. Glycaemic variability is currently defined by a large and increasing number of metrics, representing either short-term (within-day and between-day variability) or long-term glycaemic variability, which is usually based on serial measurements of HbA 1c or other measures of glycaemia over a longer period of time. In this Review, we discuss recent evidence examining the association between glycaemic variability and diabetes-related complications, as well as non-pharmacological and pharmacological strategies currently available to address this challenging aspect of diabetes management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also complicates both the achievement of recommended glycated hemoglobin (HbA1c) and time in range (TIR) targets [101, 102].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [101]
In the citing paper
“increased risk of cardiovascular disease18–20”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [19]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Feig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Quagliaro, L., Piconi, L., Assaloni, R., Martinelli, L., Motz, E., & Ceriello, A. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2795 · Cited by 772
Self-citationEfficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Research works printed but not linked: 4
- Fleisher, 2017, Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial, Diabetes Care, 40, 777, 10.2337/dc16-2426 · DOI
- Fleisher, 2017, Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial, Diabetes Care, 40, e164
- Monnier, 2016, Comment on the FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk, Diabetes Care, 39, e186, 10.2337/dc16-1133 · DOI
- 2018, 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018, Diabetes Care, 41, S73
Cited by
Sorted by citations
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationPapachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 519
Diabetes mellitus: an overview of the types, symptoms, complications and management
Cloete, L. M. (2021) · Nursing Standard · doi:10.7748/ns.2021.e11709 · Cited by 384
Li, D., Chen, K., Tang, H., Hu, S., Xin, L., Jing, X., He, Q., Wang, S., Song, J., Mei, L., et al. (2021) · Advanced Materials · doi:10.1002/adma.202108430 · Cited by 327
de Bock, M. I., Ethel Codner, D., Craig, M. E., Huynh, T., Maahs, D. M., Mahmud, F. H., Marcovecchio, L., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13455 · Cited by 282
Metadata
- Authors
- Ceriello, A., Monnier, L., & Owens, D.
- Affiliations
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Université de Montpellier (FR)
- Swansea University (GB)
- Corresponding author
- Ceriello, Antonio
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 7
- Issue
- 3
- Pages
- 221-230
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2886853964
- Cited by
- 588
- References
- 107
- Citations by year
- 2026: 58 · 2025: 71 · 2024: 78 · 2023: 81 · 2022: 81 · 2021: 96 · 2020: 87 · 2019: 36
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- glycemic variability, diabetes mellitus, glucose homeostasis, glycaemic excursions, hyperglycemia, hypoglycemia, diabetes complications, HbA1c, diabetes management, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Blood Glucose Self-Monitoring, Monitoring, Ambulatory, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
